Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
The Axcelis Technologies Inc (ACLS) news page on Stock Titan aggregates company announcements, industry event participation and regulatory disclosures focused on its role in the semiconductor equipment market. Axcelis describes itself as a leading supplier of enabling ion implantation solutions for the semiconductor industry, with more than 45 years of experience providing high-productivity systems and lifecycle support.
Investors and industry followers can use this page to monitor Axcelis’ updates on product launches, technology platforms and market engagement. Recent news has highlighted the introduction of the Purion Power Series+ ion implant platform for next generation power devices, including silicon carbide (SiC) power devices and superjunction architectures, as well as the GSD Ovation ES high current implanter for engineered substrates. Company releases also cover its participation in major industry events such as SEMICON Japan and the International Conference on Silicon Carbide and Related Materials (ICSCRM), where Axcelis technologists present technical work on SiC and related materials.
The feed also includes financial and corporate developments, such as quarterly results announcements, conference call schedules and Axcelis’ participation in investor conferences. A significant recent development is the all-stock merger agreement with Veeco Instruments Inc., under which Veeco is expected to become a wholly owned subsidiary of Axcelis, subject to regulatory and shareholder approvals.
By following this ACLS news page, readers can track Axcelis’ communications on its ion implantation product portfolio, aftermarket strategy, global customer engagement and planned combination with Veeco, all drawn from official press releases and SEC-referenced materials.
Axcelis Technologies (NASDAQ: ACLS), a key supplier of ion implantation solutions for the semiconductor industry, has inaugurated new service offices in Chitose, Hokkaido, and Kumamoto, Kyushu, Japan. These offices, which opened in June 2024, aim to enhance support for the company's expanding customer base in Japan. Axcelis President and CEO Russell Low emphasized the company's commitment to innovation and market share growth. Charles Pieczulewski, Axcelis Japan Country Manager, noted the strategic positioning of the new offices to improve support for Purion ion implant equipment and foster relations with both Silicon (Si) and Silicon Carbide (SiC) semiconductor power device customers, enabling advancements in logic production capacity.
Axcelis Technologies (NASDAQ: ACLS) has announced its participation in the 16th Annual CEO Investor Summit 2024, scheduled for July 10th at the St. Regis Hotel in San Francisco, CA.
Axcelis, a key supplier of ion implantation solutions for the semiconductor industry, will present at the event. Presentation materials will be available on the company's investor webpage.
Axcelis Technologies (Nasdaq: ACLS) will host a hybrid Investor Event on July 11, 2024, at the St. Regis Hotel, San Francisco. The event, aimed at the investment community, will run from 8 a.m. to 11 a.m. PT, with presentations starting at 9 a.m. PT. These presentations will cover Axcelis' business, growth strategy, and financial outlook. All executive officers will be present. Interested investors can attend in person or via a live audio webcast. More details and registration links are available on Axcelis’ website.
Axcelis Technologies, Inc. (NASDAQ: ACLS) announced its participation in several upcoming investor conferences, providing a platform for management to engage with investors and discuss the company's offerings for the semiconductor industry.
Axcelis Technologies, Inc. (ACLS) announced financial results for Q1 2024, reporting revenue of $252.4 million, a gross margin of 46%, and EPS of $1.57. Despite revenue decline from the previous quarter, the company exceeded guidance and highlighted growth in the implant intensive power device segment and shipments to China. The CEO mentioned continued strong execution and product success, while the CFO emphasized robust cash flow and a positive outlook for 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.